## Hemlibra (emicizumab) **Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

## MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:			

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:		

ΜΕΠΙΟΛΤΙΟΝ	DISPENSING INFORMATION	
WEDICATION		

MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:	
		THERAPY/REFILLS:		
NEW THERAPY	RENEWAL IF	FRENEWAL: DATE THERAPY	NITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):				
Continued on next page				

Continued on next page

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 4.15.25 CAT009



## Hemlibra (emicizumab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:				
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?					
YES (if yes, complete below) MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	NO DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
Congenital Hemophilia A with inhibitors Congenital Hemophilia A without inhibitors Other diagnosis: ICD-10 Code(s):					
TO SUPPORT A PRIOR AUTHORIZ					
Is patient going to be using drug	in combination with a clinical trial?	P □ Yes □ No			
Does the patient have a diagnosis of congenital hemophilia A, as corroborated by a submitted lab report documenting factor VIII deficiency or dysfunction?* $\Box$ Yes $\Box$ No					
Is Hemlibra prescribed by a hema	tologist or a clinician in a hemoph	ilia clinic? □ Yes □ No			
For diagnosis of Congenital Hemophilia A with inhibitors, please answer the following: Does the patient have a history of a high titer of factor VIII inhibitors (neutralizing anti-factor VIII alloantibodies) equaling 5 Bethesda units per milliliter or greater, as corroborated by a submitted lab report?*  _ Yes  _ No					
Select if the patient has received <u>EPISODIC</u> or <u>PROPHYLACTIC</u> treatment for at least six months with the following bypassing agent(s): Activated prothrombin complex concentrate Recombinant factor VIIa					
Has the patient experienced at least 6 bleeding events in the previous 6 months while receiving EPISODIC treatment with at least one of the aforementioned bypassing agents? $\Box$ Yes $\Box$ No					
Has the patient experienced at least 2 bleeding events in the previous 6 months while receiving PROPHYLACTIC treatment with at least one of the aforementioned bypassing agents?   Yes  No *Please provide lab report.					
For diagnosis of Congenital Hemophilia A without inhibitors, please answer the following: Does patient have documentation of optimally dosed prophylactic factor VIII product is ineffective for the prevention of spontaneous bleeding events(such as continuing to have bleeding events or arthroscopic changes within a target joint)? □ Yes □ No Please submit chart documentation.					



## Hemlibra (emicizumab) **Prior Authorization Request Form** Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_

Does patient have severe hemophilia A without inhibitors as documented with endogenous factor VIII levels less than 1% of normal factor VIII (<0.01IU/ml),? 
Ves 
No Please submit lab report.

Does patient have moderate hemophilia A without Inhibitors as documented with endogenous factor VIII levels > 1% <5% (greater than or equal to 0.01IU/ml to less than 0.05IU/ml)? 
Yes 
No Please submit lab report.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640 MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

